Your browser doesn't support javascript.
loading
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
Ouwerkerk, W; Voors, A A; Anker, S D; Cleland, J G; Dickstein, K; Filippatos, G; van der Harst, P; Hillege, H L; Lang, C C; Ter Maaten, J M; Ng, L L; Ponikowski, P; Samani, N J; van Veldhuisen, D J; Zannad, F; Metra, M; Zwinderman, A H.
Afiliación
  • Ouwerkerk W; Department of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Voors AA; Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Anker SD; Innovative Clinical Trials, Department of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Robert-Koch-Straße 40 37075, Göttingen, Germany.
  • Cleland JG; National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, Sydney St, Chelsea, London SW3 6NP, UK.
  • Dickstein K; University of Bergen, 5007 Bergen, Norway.
  • Filippatos G; Stavanger University Hospital, Gerd-Ragna Bloch Thorsens Gate 8, 4011 Stavanger, Norway.
  • van der Harst P; Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Hillege HL; Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Lang CC; National and Kapodistrian University of Athens, School of Medicine & Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, 1, Rimini Str, Haidari, 124 62 Athens, Greece.
  • Ter Maaten JM; Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Ng LL; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK.
  • Ponikowski P; Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, 50-981 Wroclaw, Poland.
  • Samani NJ; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK.
  • van Veldhuisen DJ; Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Zannad F; Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, 50-981 Wroclaw, Poland.
  • Metra M; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health; University of Brescia, Piazza del Mercato, 15, 25121 Brescia, Italy.
  • Zwinderman AH; Department of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Eur Heart J ; 38(24): 1883-1890, 2017 Jun 21.
Article en En | MEDLINE | ID: mdl-28329163
ABSTRACT

INTRODUCTION:

Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers. METHODS AND

RESULTS:

BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died during the uptitration period (n = 151) and patients with a LVEF > 40% (n = 242) were excluded. Median follow up was 21 months. We studied 2100 HFrEF patients (76% male; mean age 68 ±12), of which 22% achieved the recommended treatment dose for ACE-inhibitor/ARB and 12% of beta-blocker. There were marked differences between European countries. Reaching <50% of the recommended ACE-inhibitor/ARB and beta-blocker dose was associated with an increased risk of death and/or heart failure hospitalization. Patients reaching 50-99% of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had comparable risk of death and/or heart failure hospitalization to those reaching ≥100%. Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had the highest mortality rate (for ACE-inhibitor/ARB HR 1.72; 95% CI 1.43-2.01; for beta-blocker HR 1.70; 95% CI 1.36-2.05).

CONCLUSION:

Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reaching ≥100%.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de la Enzima Convertidora de Angiotensina / Antagonistas Adrenérgicos beta / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur Heart J Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de la Enzima Convertidora de Angiotensina / Antagonistas Adrenérgicos beta / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur Heart J Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos